Compare MAMA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | ZURA |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.1M | 455.4M |
| IPO Year | 2011 | N/A |
| Metric | MAMA | ZURA |
|---|---|---|
| Price | $14.93 | $3.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $19.00 | $13.00 |
| AVG Volume (30 Days) | 471.4K | ★ 892.6K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $95,420,129.00 | N/A |
| Revenue This Year | $31.09 | N/A |
| Revenue Next Year | $16.12 | N/A |
| P/E Ratio | $298.20 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $7.82 | $1.00 |
| 52 Week High | $17.85 | $7.25 |
| Indicator | MAMA | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 36.79 |
| Support Level | $14.26 | $3.25 |
| Resistance Level | $16.19 | $4.12 |
| Average True Range (ATR) | 0.78 | 0.24 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 66.41 | 36.21 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.